Clinical Trials

Abstract - 03292023 - OpID External Velos ResDB MD ITS 203292023 - OpID External Velos ResDB MD ITS 2

MC - Chippewa Falls Center

2655 CTY HWY I

CHIPPEWA FALLS, WI 54729

MC - Wausau Center

2727 PLAZA DRIVE

WAUSAU, WI 54401

MC - Wisconsin Rapids Center

220 24TH ST SOUTH

WISCONSIN RAPIDS, WI 54494

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI 54449

MMC - Minocqua

9576 Highway 70

MINOCQUA, WI 54548

MMC - Rice Lake

1700 W STOUT ST

RICE LAKE, WI 54868

MMC - River Region at Stevens Point

4100 State Highway 66

Stevens Point, WI 54482

MMC - Weston

3400 Ministry Parkway

WESTON, WI 54476

This phase III trial studies how well ibrutinib and obinutuzumab with or without venetoclax work in treating patients with chronic lymphocytic leukemia. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as obinutuzumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as venetoclax, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ibrutinib, obinutuzumab and venetoclax may work better in treating patients with chronic lymphocytic leukemia.

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI 54449

Neuropsychological and behavioral assessments are a crucial component of monitoring for late effects in patients being treated, normally quite aggressively, for cancer. This is especially true for patients that are exposed to potentially neurotoxic therapies. However, lack of compliance with assessment schedules, variations in assessment schedules and neuropsychological measures utilized across studies, as well as overly complex and long neuropsychological assessments have proved to be problematic to the assessment process within the Children's Oncology Group (COG). In order to remediate these problems, a streamlined and standardized neuropsychological and behavioral assessment battery has been developed. The COG Standard Neuropsychological and Behavioral Battery is a focused assessment of critical functional domains that have been empirically shown to be most affected by childhood cancer, its treatment, or other disease related factors. This battery was designed to provide a brief measure of neuropsychological and behavioral function in order to strike a balance between research goals, the clinical needs of the patient, and time constraints on the institutional neuropsychologist/psychologist. The battery of tests will take only about 1 hour to administer and all patients will be tested at 3 standardized timepoints. Parent-completed questionnaires will also be utilized to gather information about the patient's function, specifically in terms of attention, memory, executive abilities, and behavioral/social/emotional adaptation.

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI 54449

MATCH Treatment Subprotocol Z1K

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI 54449

zzzMarshfield Medical Center

611 Saint Joseph Ave

Marshfield, WI 54449

This pivotal, phase 3 study is designed to confirm the efficacy and safety of setmelanotide, a potent melanocortin receptor type (MC4R) agonist, for the treatment of obesity and hyperphagia in patients with Bardet Biedl syndrome (BBS) or Alstrom syndrome (AS).

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI 54449

zzzMarshfield Medical Center

611 Saint Joseph Ave

Marshfield, WI 54449

Evaluate the change in level of self-reported financial burden from baseline (within 60 days of diagnosis) to 12 months after diagnosis of colon or rectal cancer treated with curative-intent.

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI 54449

This randomized phase II trial studies how well multi-epitope folate receptor alpha peptide vaccine, sargramostim, and cyclophosphamide work in treating patients with triple negative breast cancer. Vaccines made from a person's white blood cells mixed with tumor proteins may help the body build an effective immune response to kill tumor cells. Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving multi-epitope folate receptor alpha peptide vaccine, sargramostim, and cyclophosphamide may work better in treating patients with triple negative breast cancer.

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI 54449

This phase II trial studies Trk inhibitor LOXO-101 in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with NTRK fusions that have spread to other places in the body and have come back or do not respond to treatment. Trk inhibitor LOXO-101 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI 54449

This phase II trial studies how well pan-FGFR tyrosine kinase inhibitor JNJ-42756493 works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders that have spread to other places in the body and have come back or do not respond to treatment with FGFR mutations. Pan-FGFR tyrosine kinase inhibitor JNJ-42756493 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI 54449

This phase II trial studies how well tazemetostat works in treating patients with solid tumors, non-hodgkin lymphoma, or histiocytic disorders that have spread to other places in the body and have come back or do not respond to treatment and have EZH2, SMARCB1, or SMARCA4 gene mutations. Tazemetostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI 54449